Obstructive Sleep Apnea (OSA)
This patient is at greatest risk for cardiovascular complications, specifically stroke, heart failure, and difficult-to-control hypertension, all of which are strongly associated with untreated obstructive sleep apnea.
Clinical Presentation Analysis
This 70-year-old obese man (BMI ~37 kg/m²) presents with the classic triad of OSA:
- Excessive daytime fatigue despite adequate sleep time
- Loud snoring (worsening pattern noted by spouse)
- Anatomic findings: thick tongue suggesting upper airway narrowing
His existing comorbidities—hypertension and hyperlipidemia—are not coincidental but rather strongly associated with OSA 1.
Why Cardiovascular Disease is the Primary Risk
The evidence is unequivocal that OSA independently increases cardiovascular morbidity and mortality through several mechanisms 1:
Specific Cardiovascular Risks in This Patient:
Stroke: OSA is independently associated with stroke risk, and the AHA/ASA stroke prevention guidelines emphasize that sleep apnea severity correlates with increasing stroke risk 2. In older adults with OSA, cardiovascular comorbidities are particularly prominent 1.
Resistant Hypertension: His blood pressure of 140/80 may represent difficult-to-control hypertension. OSA should be suspected in all patients with hypertension, especially when resistant to treatment 1. The guidelines specifically state that hypertension in OSA is "often difficult to control" 1.
Heart Failure: OSA is associated with both systolic and diastolic heart failure 1. The repetitive hypoxemia and arousals cause hemodynamic stress, increasing pulmonary and systemic arterial pressures 1.
Atrial Fibrillation: OSA increases risk of significant arrhythmias 1.
Key Diagnostic Considerations
This patient meets multiple high-risk criteria for OSA 1, 3:
- Age ≥70 years
- BMI ≥33 kg/m² (his BMI ~37)
- Hypertension requiring treatment
- Excessive daytime sleepiness/fatigue
- Witnessed snoring
- Anatomic upper airway narrowing (thick tongue)
Important Clinical Pitfall:
Absence of reported sleepiness is less useful than presence of symptoms 3. Many older adults with OSA don't report classic "sleepiness" but rather present with fatigue, as this patient does 1, 4. Additionally, 51% of OSA patients have no excessive daytime sleepiness 5, so its absence doesn't exclude the diagnosis.
Pathophysiologic Mechanisms
The cardiovascular risk stems from:
- Repetitive hypoxemia causing oxidative stress and inflammation
- Autonomic nervous system activation with each apneic episode
- Increased systemic and pulmonary arterial pressures during apneas 1
- Endothelial dysfunction and accelerated atherosclerosis
- Sleep fragmentation from recurrent arousals 1
Additional Comorbidity Considerations
Beyond cardiovascular disease, this patient faces risks for:
- Diabetes mellitus: Strong association between OSA and insulin resistance 1
- Metabolic syndrome: Present in 86% of hypertensive patients with OSA 5
- Neurocognitive impairment: OSA contributes to decreased quality of life and cognitive dysfunction in older adults 1
- Nocturia: Commonly misattributed to prostatic hypertrophy in males but frequently caused by OSA 1
Immediate Clinical Action Required
Polysomnography is indicated to confirm diagnosis and severity 1, 6. The patient's presentation warrants expedited testing given his high-risk profile 6.
The mortality impact is significant: untreated OSA increases mortality in patients under 50, though the impact in older populations remains under investigation 1. However, the cardiovascular morbidity is well-established across all age groups 1, 2.
Treatment with CPAP, if OSA is confirmed, can reduce cardiovascular event risk substantially. Studies show adjusted hazard ratios of 0.34 for cardiovascular events with CPAP treatment 2, and blood pressure reductions of 1.4-7.2 mm Hg 2.